Search

REVOLUTION Medicines Inc

Закрыт

СекторЗдравоохранение

203.4 -0.94

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

199.66

Макс.

206.37

Ключевые показатели

By Trading Economics

Доход

-644M

-1.1B

Прибыль на акцию

-2.34

Сотрудники

883

EBITDA

-184M

-621M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+23.69% upside

Дивиденды

By Acuity

Следующий отчет о доходах

4 нояб. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

6.2B

45B

Предыдущая цена открытия

204.34

Предыдущая цена закрытия

203.4

Новостные настроения

By Acuity

76%

24%

308 / 339 Рейтинг в Healthcare

REVOLUTION Medicines Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

11 сент. 2026 г., 20:08 UTC

Revolution Medicines Inc shares are higher during Friday's session, despite earlier pulling back from an intraday high. No specific news was identified for the movement.

3 сент. 2026 г., 19:16 UTC

News

Revolution Medicines Inc shares are higher after positive Phase 1/2 trial results for RASONQUE in advanced RAS mutant non-small cell lung cancer were published.

2 сент. 2026 г., 23:51 UTC

News

Revolution Medicines shares rise in after-market trading following positive Phase 1/2 data on RASONQUE for advanced RAS mutant non-small cell lung cancer.

1 сент. 2026 г., 23:06 UTC

Revolution Medicines Inc shares are higher in after-market trading, maintaining a stable performance since Tuesday's close despite earlier session volatility.

31 авг. 2026 г., 20:07 UTC

Correlated Moves
News

Revolution Medicines Inc shares are lower amid broader market pressures and concerns from the Jackson Hole Economic Symposium regarding inflation and monetary policy tightening.

28 авг. 2026 г., 20:02 UTC

Social Media
News

Revolution Medicines shares are lower amid significant selling pressure, despite recent price target increases by UBS and others for its drug RASONQUE.

27 авг. 2026 г., 23:02 UTC

News

Revolution Medicines Inc shares are higher in after-market trading following FDA approval of RASONQUE for metastatic pancreatic cancer, discussed during an August 26 conference call.

26 авг. 2026 г., 23:21 UTC

News
Social Media

Oppenheimer raised Revolution Medicines' price target to $260, citing FDA approval of RASONQUE for advanced pancreatic cancer, as shares trade higher in after-market hours.

25 авг. 2026 г., 20:07 UTC

News

Revolution Medicines Inc received a "Moderate Buy" rating from brokerages. Needham raised its price target to $240, while shares are trading roughly flat.

24 авг. 2026 г., 20:06 UTC

Revolution Medicines Inc shares are higher today, recovering from an earlier low. The stock has gained since Friday's close amid rising oil prices.

21 авг. 2026 г., 19:46 UTC

News

Revolution Medicines shares are lower today as Bernstein raised its price target to $179, continuing a trend of three consecutive daily declines.

20 авг. 2026 г., 23:26 UTC

Revolution Medicines Inc. shares were roughly flat in after-market hours, remaining above the 20-day moving average and near the upper end of their one-month range.

19 авг. 2026 г., 19:46 UTC

News

Revolution Medicines Inc shares are lower Wednesday, pulling back after reaching a session high. The stock has declined since Tuesday's close.

17 авг. 2026 г., 19:51 UTC

Social Media

Revolution Medicines shares are higher since Friday's close as Baker Bros boosts its stake to 11.4 million shares, valued at $2 billion.

13 авг. 2026 г., 19:36 UTC

Revolution Medicines Inc shares are lower, reaching a session low earlier. This decline follows a cumulative drop since Wednesday's close.

12 авг. 2026 г., 23:16 UTC

Revolution Medicines shares declined in after-market trading, despite earlier gains. The Consumer Price Index report showed a modest rise in consumer prices today.

11 авг. 2026 г., 19:36 UTC

News

Revolution Medicines Inc is trading lower as broader geopolitical tensions and upcoming U.S. inflation reports weigh on market sentiment.

10 авг. 2026 г., 23:51 UTC

Revolution Medicines Inc. shares were roughly flat in after-market hours, maintaining a position above the 20-day moving average and near the one-month range's upper end.

7 авг. 2026 г., 19:11 UTC

News

Revolution Medicines Inc shares are higher as the company plans a Phase 3 study and Wedbush raises its price target to $201 from $192.

6 авг. 2026 г., 19:36 UTC

Social Media
News

Revolution Medicines Inc is trading higher as RBC Capital and Evercore ISI raise price targets, reflecting growing confidence in the company's clinical pipeline.

5 авг. 2026 г., 23:02 UTC

Social Media
News

Revolution Medicines shares lower in after-market trading following a second-quarter loss of $644.4 million and an EPS of -$3.06, missing estimates.

4 авг. 2026 г., 23:06 UTC

Revolution Medicines shares are lower in after-market trading, settling near Tuesday's close. The stock remains above its 20-day moving average.

3 авг. 2026 г., 23:26 UTC

Revolution Medicines Inc shares are trading higher in after-market hours. Broader market sentiment is positive, influenced by declining oil prices and reduced inflation concerns.

31 июл. 2026 г., 20:06 UTC

Revolution Medicines Inc. shares are lower amid broader market volatility and rising U.S. Treasury yields, which have heightened inflation concerns and interest rate expectations.

30 июл. 2026 г., 22:41 UTC

Revolution Medicines Inc. shares are lower in after-market trading, declining since Thursday's close amid fluctuations in bond yields and Fed policy uncertainty.

29 июл. 2026 г., 17:02 UTC

Revolution Medicines Inc shares are lower, continuing a four-session decline with unusually high trading volume. The stock remains below its 20-day moving average.

28 июл. 2026 г., 19:02 UTC

Revolution Medicines Inc shares are lower today, continuing a decline since Monday amid negative broader market sentiment following significant drops in Asian markets.

27 июл. 2026 г., 20:06 UTC

Revolution Medicines Inc shares are lower amid broader market dynamics, including a decline in oil prices and falling Treasury yields ahead of the Federal Reserve meeting.

24 июл. 2026 г., 18:26 UTC

Social Media
News

Revolution Medicines shares are lower amid broader market sentiment, despite RJ's increased price target of $230 and positive FDA news on daraxonrasib.

22 июл. 2026 г., 18:26 UTC

Revolution Medicines Inc shares are higher today amid broader geopolitical tensions affecting market sentiment, despite no specific company news driving the movement.

Сравнение c конкурентами

Изменение цены

REVOLUTION Medicines Inc Прогноз

Целевая цена

By TipRanks

23.69% рост

Прогноз на 12 месяцев

Средняя 252.053 USD  23.69%

Максимум 320 USD

Минимум 179 USD

Основано на мнении 21 аналитиков Wall Street, спрогнозировавших целевые цены для REVOLUTION Medicines Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

21 ratings

20

Покупка

1

Удержание

0

Продажа

Настроения

By Acuity

308 / 339Рейтинг в Здравоохранение

Новостные настроения

Сильные свидетельства нисходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
help-icon Live chat